Tisotumab Vedotin demonstrates superior survival outcomes in Advanced Cervical Cancer

CAR-T Digest - August 2020

03 July 2024: Tisotumab Vedotin demonstrates superior survival outcomes in Advanced Cervical Cancer

Tisotumab vedotin showed a 30% lower risk of death compared to chemotherapy in advanced cervical cancer
Similar adverse event rates were observed between tisotumab vedotin and chemotherapy
Phase 3 innovaTV 301 trial demonstrated significantly longer overall survival (11.5 vs. 9.5 months) and progression-free survival (4.2 vs. 2.9 months) with tisotumab vedotin
Patients treated with tisotumab vedotin had a higher objective response rate (17.8% vs. 5.2%) compared to chemotherapy
Majority of patients experienced at least one adverse event; grade 3 or greater events were slightly lower with tisotumab vedotin (52%) than chemotherapy (62.3%)
Findings support tisotumab vedotin as a promising second-line or third-line treatment option for recurrent cervical cancer, potentially superior to chemotherapy